BlackRock Fund Advisors has recently announced that it has increased stake in Inovio Pharmaceuticals Inc. (NASDAQ:INO) by 43.81%. After grabbing 11.13 million shares, the institutional investor is now in possession of 3.39 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 7.04% having worth around $216.31 million. Moreover, The Vanguard Group, Inc. increased its share by 3.77 million to have a control over 9.13 million shares. And SSgA Funds Management, Inc. raised its holdings to 5.33 million shares by acquiring 7.07 million shares or 4.47% of the stake.
Inovio Pharmaceuticals Inc. (INO) concluded trading on 08/26/20 at a closing price of $12.73, with 7.7 million shares of worth about $98.03 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -12.02% during that period and on Wednesday the price saw a gain of about 0.87%. Currently the company’s common shares owned by public are about 167.52M shares, out of which, 164.19M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 8 analysts are covering the INO stock and their offered price forecasts bring an average price target of $19.38. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $36.00 and could fall to a lowest price of $8.00. Analysts also issued an outlook of 2.90 for the Inovio Pharmaceuticals Inc. stock for next 12 months. The stock’s current price level is 33.0% above of average price target set by the analysts, while a rise to estimated low would result in loss of -59.13 for the stock. However, touching the estimated high of $36.00 would mean a gain of 64.64% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 46 times over the past 12 months. They bought 592,195 shares in 26 of the transactions. In 20 selling transactions, insiders dumped 379,248 shares.
SPDR S&P Biotech ETF, Vanguard Total Stock Market Index, and iShares Russell 2000 ETF are the top 3 mutual funds which are holding stakes in Inovio Pharmaceuticals Inc. SPDR S&P Biotech ETF is currently holding 4.46 million shares of worth totaling $86.72 million. The company recently came selling 44688.0 shares which brought its stake up to 2.82% of the company’s outstanding shares. Vanguard Total Stock Market Index sold 31887.0 shares, after which its hold over company’s outstanding shares shrunk to 2.70%, leaving 4.26 million shares with the mutual fund that have a worth of about $82.85 million. iShares Russell 2000 ETF, after selling 2.96 million shares, have now control over 1.87% of the stake in the company. It holds -0.14 million shares of worth $57.59 million.
Inovio Pharmaceuticals Inc. (NASDAQ: INO) started trading at $12.59, below -$0.03 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $12.73, or with a gain of 0.87%. Stock saw a price change of -12.02% in past 5 days and over the past one month there was a price change of -38.77%. Year-to-date (YTD), INO shares are showing a performance of 285.76% which increased to 494.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.91 but also hit the highest price of $33.79 during that period. While comparing its average daily trading volume of 32.29 million shares, we see that about 7.7 million changed hands on the day. The stock is currently trading -24.46% below its 20-day simple moving average (SMA20), while that difference is down -37.91% for SMA50 and it goes to 24.36% higher than SMA200.
BlackRock Fund Advisors acquired 11.13 million shares of Inovio Pharmaceuticals Inc. having value of about $216.31 million. Data submitted at the U.S SEC by BlackRock Fund Advisors revealed that the firm now holds 3.39 million shares in the company valued at close to $43153745.25, or have control over 43.81% stake in the company. Inovio Pharmaceuticals Inc. (NASDAQ: INO) currently have 167.52M outstanding shares and institutions hold larger chunk of about 34.10% of that. Holding of mutual funds in the company is about 19.68% while other institutional holders and individual stake holders have control over 2.54% and 16.01% of the stake respectively.
The stock has a current market capitalization of $2.25B and its 3Y-monthly beta is at 1.30. It has posted earnings per share of -$1.70 in the same period. It has Quick Ratio of 10.10 while making debt-to-equity ratio of 0.43. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INO, volatility over the week remained 8.57% while standing at 9.90% over the month.
Analysts are in expectations that Inovio Pharmaceuticals Inc. (INO) stock would likely to be making an EPS of -$0.19 in the current quarter, while forecast for next quarter ESPS is -$0.19 and it is $0.6 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.26 which is -$0.1 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.25 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -15.40% while it is estimated to increase by 140.80% in next year. EPS is likely to grow at an annualized rate of 0.00% for next 5-years, compared to annual growth of -14.60% made by the stock over the past 5-years.
Analysts at 8 brokerage firms have issued recommendations for the Inovio Pharmaceuticals Inc. (INO)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.90. Out of those 8 Wall Street analysts, 2 recommended a “Buy” rating, while 5 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on July 01, 2020 offering a Sell rating for the stock and assigned a target price of $11 to it. Coverage by Maxim Group stated Inovio Pharmaceuticals Inc. (INO) stock as a Hold in their note to investors on July 01, 2020, suggesting a price target of for the stock. On June 29, 2020, H.C. Wainwright Downgrade their recommendations, while on June 26, 2020, Stifel Downgrade their ratings for the stock with a price target of $24. Stock get a Buy rating from The Benchmark Company on May 21, 2020.